Clinical Research Center for Dementia of South Korea (CREDOS)(or CRCD)
NCT ID: NCT01198093
Last Updated: 2012-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
800 participants
OBSERVATIONAL
2005-11-30
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. the diagnostic criteria of Alzheimer's disease(AD) according to DSM IV or NINCDS -ADRDA
2. the diagnostic criteria of mild cognitive impairment(MCI) A. Memory or other cognitive complaint preferably corroborated by an informant B. Objective memory impairment or other cognitive for age and education C. Largely intact general cognitive function D. Essentially preserved ADL E. Not demented
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health & Welfare, Korea
OTHER_GOV
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Doh Kwan Kim
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Doh K KIm, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Ministry of Health and Welfare
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, Kangnam-Ku, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Doh Kwan Kim, M.D and Ph.D
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Lee YM, Park JM, Lee BD, Moon E, Jeong HJ, Chung YI, Kim JH, Kim HJ, Mun CW, Kim TH, Kim YH. Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naive Alzheimer's disease patients. J Clin Psychiatry. 2016 Jan;77(1):e8-13. doi: 10.4088/JCP.14m09740.
Yoon B, Shim YS, Cheong HK, Hong YJ, Lee KS, Park KH, Ahn KJ, Kim DJ, Kim YD, Choi SH, Yang DW. White matter hyperintensities in mild cognitive impairment: clinical impact of location and interaction with lacunes and medial temporal atrophy. J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):e365-72. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.040. Epub 2014 Feb 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-02-008
Identifier Type: -
Identifier Source: org_study_id